The two active ingredients in Epclusa, a potent antiviral drug, are sofosbuvir (400 mg) and velpatasvir (100 mg) in a fixed-dose combination. Chronic hepatitis C virus (HCV) infection in all major genotypes (1–6) is treated with this oral medicine. Epclusa is a ground-breaking treatment for HCV management because of its once-daily oral dosage, high cure rates, and broad-spectrum efficacy.

Epclusa is manufactured by Gilead Sciences and has been approved by key health agencies such as the European Medicines Agency (EMA), the U.S. FDA, and WHO prequalification, indicating its clinical efficacy and worldwide recognition.

Composition:

Sofosbuvir 400 mg: A nucleotide analog polymerase inhibitor that targets the NS5B RNA-dependent RNA polymerase enzyme to prevent HCV replication.

Velpatasvir (100 mg) is an NS5A inhibitor that interferes with the formation of virion and replication of viral RNA.

These two substances function in concert to halt the HCV replication cycle and eliminate the virus from the body.

Indications:

Epclusa is advised for the treatment of chronic hepatitis C virus infection in adults and children 6 years of age or older, regardless of HCV genotype, weighing at least 17 kg. It is very helpful in:

Patients who have never had treatment and those who have

Individuals that have compensated cirrhosis or not

Using ribavirin in patients with decompensated cirrhosis

Patients who are co-infected, such as those with HIV and HCV

Dosage and Administration:

One tablet Sofosbuvir+Velpatasvir 400mg+100mg (Epclusa) taken once daily, with or without food, is the recommended dosage.

Treatment typically lasts 12 weeks for most patients. Epclusa is used in conjunction with ribavirin for individuals with decompensated cirrhosis, and they might need more medical attention.

Regarding duration, dose adjustments, or co-medications, patients should heed the advice of their healthcare professional.

Action Mechanism:

Epclusa targets two different proteins that are necessary for the replication of HCV:

Chain termination results from sofosbuvir’s incorporation into the viral RNA chain, which mimics a natural nucleotide.

Velpatasvir disrupts viral replication and assembly by interfering with the NS5A protein.

Epclusa produces sustained virologic response (SVR) rates of over 95% by targeting several stages of the viral life cycle, effectively producing a functional cure.

Benefits of Epclusa:

Effective against each of the six main HCV genotypes, pan-genotypic

High cure rates: clinical trials showed an SVR of above 95%.

Easy dosage: One tablet, once daily

Few adverse effects

suitable for people with renal or hepatic impairment (with considerations)

Side Effects:

In general, Epclusa is well tolerated. Nonetheless, certain patients might encounter:

A headache

Weariness

Feeling queasy

Sleeplessness

Having diarrhea

Anemia is one of the additional negative effects that might happen when ribavirin is used with it. If a patient experiences any odd or severe symptoms, they should inform their healthcare professional.

Warnings and Precautions:

It is not advised to use this medication when pregnant or nursing, particularly if ribavirin is also being taken.

Drug interactions: amiodarone, rifampin, antacids, and several HIV medicines may interact with epclusa. Before using Epclusa in conjunction with other treatments, always get medical advice.

Hepatitis B reactivation: In order to prevent viral reactivation, Epclusa must be started after screening for the hepatitis B virus (HBV).

Storage Instructions:

Keep at room temperature, which is lower than 30°C (86°F).

To keep it dry, keep it in its original container.

Keep out of children’s reach.

Contraindications:

Intolerance to velpatasvir, sofosbuvir, or any ingredient in the formulation

It is not advised to use with strong P-gp or CYP enzyme inducers (such as rifampin or carbamazepine).

Accessible:

Epclusa comes in bottles or blister packs, with a 4-week supply of 28 tablets on average. Under licensed agreements, generic versions are accessible in a number of nations and offer affordable substitutes.

Conclusion:

Epclusa (400 mg of sofosbuvir plus 100 mg of velpatasvir) is a significant improvement in hepatitis C treatment. Patients and healthcare professionals throughout the world choose it for its comprehensive genotypic coverage, high cure rates, and user-friendliness. Epclusa can successfully eradicate HCV and lessen the long-term burden of liver disease with appropriate adherence and medical supervision.

Order Now At Mdx Pharma bd….

To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.

1. Why is Epclusa (Sofosbuvir + Velpatasvir) used?
Epclusa is used to treat adults and children aged three and above who have a chronic hepatitis C virus (HCV) infection. It works well against all six of the main HCV genotypes (genotypes 1–6).

2. How is Epclusa operated?
Velpatasvir is an NS5A inhibitor, while sofosbuvir is an inhibitor of nucleotide analog polymerase. When combined, they prevent the virus from growing inside the body, resulting in a long-lasting virologic reaction (cure).

3. How does one take Epclusa?
One tablet is taken orally once a day, with or without food, for a duration of 12 weeks. Depending on the liver condition (cirrhosis, for example), the duration may change.

4. Epclusa shouldn’t be taken by whom?
It should be avoided by those who are allergic to any of its constituents or who are taking specific medications, such as St. John’s Wort or rifampin. Before beginning, always get medical advice.

5. Is it safe to take Epclusa while pregnant or nursing?
There isn’t much information available. Generally speaking, it is not advised until absolutely necessary. During treatment, women who are of reproductive age should utilize an effective form of contraception.